Sedative Adverse Reaction
11
1
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
Morphine, Midazolam and Dexmedetomidine in the Management of Acute Cardiogenic Pulmonary Edema, Safety and Efficacy
EEG-guided Propofol Sedation Versus Standard Care for Oesophagogastroduodenoscopy and Colonoscopy in Children
Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation
Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry
Pharmacist Led Intervention to Improve Medication Use in Older In-patients Living With Frailty: the Drug Burden Index
Vasopressor Requirements Depends on Sedation Strategy
The Effect of Real-time Binaural Sound on Sedation Using Dexmedetomidine
Reducing Sedatives in Hospital Study
The Use of Midazolam and Remifentanil During Dialysis Access Procedures
Evaluating the Effects of Propofol vs. Dexmedetomidine
Effect of Sedation on Pulmonary Aeration in Children